Research Summary

Selected Publications

Papers with an asterisk(*) are based on research conducted outside of RIKEN.

• 1.*Nakazeki F, Tsuge I, Horie T, Imamura K, Tsukita K, Hotta A, Baba O, Kuwabara Y, Nishino T, Nakao T, Nishiga M, Nishi H, Nakashima Y, Ide Y, Koyama S, Kimura M, Tsuji S, Naitoh M, Suzuki S, Izumi Y, Kawarai T, Kaji R, Kimura T, Inoue H, Ono K.:
  "MiR-33a is a therapeutic target in SPG4-related hereditary spastic paraplegia human neurons."
  Clinical Science CS20180980; doi:10.1042/CS20180980, (2019)
• 2.Suga M, Kondo T, Imamura K, Shibukawa R, Okanishia Y, Sagara Y, Tsukita K, Enami T, Furujo M, Saijo K, Nakamura Y, Osawa M, Saito MK, Yamanaka S, Inoue H.:
  "Generation of a human induced pluripotent stem cell line, BRCi001-A, derived from a patient with mucopolysaccharidosis type I."
  Stem Cell Research, 101406, doi:10.1016/j.scr.2019.101406, (2019)
• 3.*Karagiannis P, Takahashi K, Saito M, Yoshida Y, Okita K, Watanabe A, Inoue H, Yamashita JK, Todani M, Nakagawa M, Osawa M, Yashiro Y, Yamanaka S, Osafune K.:
  "Induced Pluripotent Stem Cells and Their Use in Human Models of Disease and Development."
  Physiological Reviews, 1;99(1):79-114, (2019)
• 4.Niki T, Imamura K, Enami T, Kinoshita M, Inoue H.:
  "Establishment of human induced pluripotent stem cell line from a patient with Angelman syndrome carrying the deletion of maternal chromosome"
  15q11.2-q13. Stem Cell Research 34(2019) 101363, doi: 10.1016/j.scr.2018.101363, (2018)
• 5.*Tsuburaya N, Homma K, Higuchi T, Balia A, Yamakoshi H, Shibata N, Nakamura S, Nakagawa H, Ikeda SI, Umezawa N, Kato N, Yokoshima S, Shibuya M, Shimonishi M, Kojima H, Okabe T, Nagano T, Naguro I, Imamura K, Inoue H, Fujisawa T, Ichijo H.:
  "A small-molecule inhibitor of SOD1-Derlin-1 interaction ameliorates pathology in an ALS mouse model."
  Nat Commun, 10;9(1):2668 (2018)
  
• 6.*Kondo T, Imamura K, Funayama M, Tsukita K, Miyake M, Ohta A, Woltjen K, Nakagawa M, Asada T, Arai T, Kawakatsu S, Izumi Y, Kaji R, Iwata N, Inoue H.:
  "iPSC-Based Compound Screening and In Vitro Trials Identify a Synergistic Anti-amyloid β Combination for Alzheimer's Disease."
  Cell Reports 21(8), 2304-2312(2017)
• 7.*Nakano-Kobayashi A, Awaya T, Kii I, Sumida Y, Okuno Y, Yoshida S, Sumida T, Inoue H, Hosoya T, Hagiwara M.:
  "Prenatal neurogenesis induction therapy normalizes brain structure and function in Down syndrome mice."
  Proceedings of the National Academy of Sciences 114(38), 10268-10273(2017)
• 8.Sekine S, Kondo T, Murakami N, Imamura K, Enami T, Shibukawa R, Tsukita K, Funayama M, Inden M, Kurita H, Hozumi I, Inoue H.:
  "Induced pluripotent stem cells derived from a patient with familial idiopathic basal ganglia calcification (IBGC) caused by a variant in SLC20A2 gene."
  Stem Cell Research, 24, 40-43 (2017)
• 9.Murakamia N, Ishikawa T, Kondo T, Imamura K, Tsukita K, Enami T, Funayama M, Shibukawa R, Matsumoto S, Izumi Y, Ohta E, Obata F, Kaji R, Inoue H.:
  "Establishment of DYT5 patient-specific induced pluripotent stem cells with a GCH1 mutation."
  Stem Cell Research, 24, 36-39 (2017)
• 10.Tan G W, Kondo T, Murakamia N, Imamura K, Enami T, Tsukita K, Shibukawa R, Funayama M, Matsumoto R, Ikeda A, Takahashi R, Inoue H.:
  "Induced pluripotent stem cells derived from an autosomal dominant lateral temporal epilepsy (ADLTE) patient carrying S473L mutation in leucine-rich glioma inactivated 1 (LGI1)."
  Stem Cell Research, 24, 12-15 (2017)

Events

Publications

Related Links

Lab Members

Contact Information